Population pharmacokinetic modeling of niraparib to assess different absorption models Poster Population pharmacokinetic modeling of niraparib to assess different absorption models CertaraNovember 22, 2024
Why Clinical Pharmacology & Pharmacometrics Should Collaborate Blog Why Clinical Pharmacology & Pharmacometrics Should Collaborate A symbiosis between a modeler and a trialist is often required to develop a model-informed…CertaraNovember 8, 2024
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population Publication A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population CertaraNovember 7, 2024
Why You Need an Integrated Development Plan Blog Why You Need an Integrated Development Plan Learn about the Integrated Development Plan for successful drug development & its relation to the…CertaraOctober 17, 2024
Academic Centers of Excellence for Model-informed Drug Development (MIDD) Fact Sheet Academic Centers of Excellence for Model-informed Drug Development (MIDD) CertaraOctober 16, 2024
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps Publication Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps CertaraOctober 16, 2024
16th Annual World ADC London 2026 Conference 16th Annual World ADC London 2026 CertaraOctober 11, 2024
Why cancer drug programs need human mass balance studies Blog Why cancer drug programs need human mass balance studies Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…CertaraSeptember 23, 2024
Resmetirom: A pioneering NASH clinical program Blog Resmetirom: A pioneering NASH clinical program Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…CertaraAugust 23, 2024